---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Budget impact model discussion"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Budget impact model discussion. Topics: Company statements on coverage and reimbursement of cretostimogene grenadenorepvec, Expected completion of the marketing application, Limitations stated by the authors of a published budget impact model, Pricing and coverage recommendations of the ICER review, and 1 further topic. 6 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics/budget-impact-model-discussion"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Budget impact model discussion

<a id="heading-4.2.7"></a>

## 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

### Summary

Task force good-practice guidance lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker and presentation as a series of scenario analyses. For cretostimogene grenadenorepvec, two of these inputs are not yet available: a price, and a labeled population and dosing schedule. CG Oncology expects to complete its BLA “before the end of March 2027” and, after FDA feedback, plans to include high-grade papillary-only disease alongside CIS with or without papillary tumors.

The eligible population depends on which BCG-unresponsive disease is included. CG Oncology estimates up to 25,000 addressable patients with BCG-unresponsive NMIBC from internal research. In the nadofaragene firadenovec budget impact model of one million members, 5.5 adults with CIS ± Ta/T1 disease were eligible in Year 1, against 33.2 when papillary-only disease was added; that model applied 56.5% BCG treatment and 30% BCG unresponsiveness. The 2020 ICER review assumed 38% BCG non-response and derived 70,135 prevalent eligible individuals, of whom 18,956 (27%) had CIS. The authors of that model state that up to 80% of patients decline or are ineligible for cystectomy.

On costs, the Form 10-K describes cretostimogene as a six-week induction course, with three weekly maintenance doses every three months for the first 12 months and every six months for the next 24 months. Comparator list prices are $62,740.70 per Adstiladrin box (“4 vials x 20 ml”; instilled once every three months; October 2026), $35,800.00 per 400 mcg Anktiva vial (January 2025), and $25,034.88 per pembrolizumab dose given every 6 weeks (September 2026); no wholesale acquisition cost was found for the gemcitabine intravesical system, whose fourth-quarter 2026 Medicare Part B payment limit is $73,054.053 per 225 mg system. Each intravesical instillation also carries administration and surveillance costs (CPT 51720, 52000, 88112), and in the nadofaragene firadenovec model increased drug and administration costs were partially offset by savings from reduced progression, fewer cystectomies, and lower adverse event rates. In the published models, results were most influenced by uptake rate, drug cost, and target population size in the budget impact model, and the 5-year Markov model was sensitive to cost alone in one-way sensitivity analysis. The budget impact model and the cost-per-responder model were funded by Ferring Pharmaceuticals and Johnson & Johnson, and the nogapendekin alfa inbakicept analysis is a preliminary report from ImmunityBio.

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/); [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/); [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates); [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599); [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf); [Ferring Adstiladrin Connecticut WAC disclosure (2026)](https://ferringusa.com/Connecticut-Adstiladrin-WAC-Pricing-Sheet); [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download); [ImmunityBio Anktiva Colorado WAC disclosure (2025)](https://immunitybio.com/wp-content/uploads/2025/06/Anktiva-Colorado-Disclosure-FINAL.pdf); [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/); [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip); [CMS Physician Fee Schedule Relative Value File (2026)](https://www.cms.gov/files/zip/rvu26d-updated-08-26-2026.zip); [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/); [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037); [ImmunityBio ISPOR 2026 health economic analysis press release (2026)](https://immunitybio.gcs-web.com/node/11506)

<a id="topic-4.2.7-2"></a>

### Company statements on coverage and reimbursement of cretostimogene grenadenorepvec

> “For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs.”
> “Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.”
> “It is possible that a third-party payor may consider our products as substitutable and offer to reimburse patients only for the less expensive product.”
> “In particular, given a significant portion of large urology practices are concentrated in a relatively small number of urology physician groups, market adoption by such groups will be an important factor in potential commercial success.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-4.2.7-3"></a>

### Expected completion of the marketing application

> “To incorporate the additional data, we now expect to complete the submission before the end of March 2027.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-4.2.7-4"></a>

### Limitations stated by the authors of a published budget impact model

> “Key limitations include reliance on projected market shares for nadofaragene firadenovec, omission of recently approved treatments (nogapendekin alfa inbakicept-pmln and TAR-200) due to the lack of publicly available market share data, and assumptions to derive clinical outcomes for certain treatments due to lack of reported data.”
> “The market share estimate for nadofaragene firadenovec is based on sponsor-conducted research and should be interpreted as exploratory rather than predictive.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.7-5"></a>

### Pricing and coverage recommendations of the ICER review

> “Manufacturers should set prices based on the added clinical value of treatments over lower-cost regimens. Leapfrogging these lower-cost regimens and setting prices relative to higher-cost options adds to the growing financial toxicity of oncology care.”
> “It seems likely that the FDA label for the emerging treatments will be limited to BCG-unresponsive patients, and payers may therefore wish to consider requiring documentation of a trial of BCG as a criterion for coverage.”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="topic-4.2.7-6"></a>

### Data sources recommended for budget impact inputs

> “Data sources for the BIA should include published clinical trial estimates and comparator studies for the efficacy and safety of the current and new interventions as well as the decision maker's own population for the other parameter estimates, where possible.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
